Trials / Completed
CompletedNCT03321825
Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the sensitivity of the Merz Cheeks Fullness Assessment Scale (MCFAS) and the clinical relevance of aesthetically pleasing outcomes by detecting changes in cheek appearance after Belotero® Volume Lidocaine injection. The safety objectives include the identification and description of adverse events (AEs), adverse device effects (ADEs), serious adverse events (SAEs), serious adverse device effects (SADEs), anticipated serious adverse device effects (ASADEs) and unanticipated adverse device effects (UADEs) during the course of the study. Additionally, common treatment site responses (CTRs) will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Belotero® Volume Lidocaine | Mode of application: subdermal injection |
Timeline
- Start date
- 2017-09-29
- Primary completion
- 2018-01-08
- Completion
- 2018-01-08
- First posted
- 2017-10-26
- Last updated
- 2018-01-19
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03321825. Inclusion in this directory is not an endorsement.